《大行》招商證券續予新東方(EDU.US)目標價63美元 維持「買入」評級
招商證券國際發表研究報告,預計新東方(09901.HK)(EDU.US)2025財年第四季收入按年升5%至12億美元,當中核心教育業務收入按年增長13%,符合公司早前發出的指引。該行提到,由於K12業務穩健增長,加上產能擴建計劃,看好公司2026財年的收入按年增長及利潤率擴張的前景。
該行表示,新東方已在4月底用盡其7億美元股票回購額度,預計公司或於7月底公佈新的股東回報計劃,計劃可能是透過派息或股票回購,成爲短期的股價催化因素。該行維持集團「買入」評級,美股目標價63美元,港股目標價49港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.